Abstract FZJ-2026-01535

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
P03.25.B CLINICAL UTILITY OF [18F]FET PET IN PATIENTS WITH CIRCUMSCRIBED ASTROCYTIC GLIOMA

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025

European Association of Neuro-Oncology, EANO 2025, PraguePrague, Czech Republic, 16 Oct 2025 - 19 Oct 20252025-10-162025-10-19 () [10.1093/neuonc/noaf193.184]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: AbstractBACKGROUNDO-(2-[18F]fluoroethyl)-L-tyrosine ([¹⁸F]FET) PET is predominantly applied for molecular imaging of diffuse gliomas. In contrast, data on the clinical utility of [¹⁸F]FET PET in circumscribed astrocytic gliomas (CAG) remain scarce.MATERIAL AND METHODSWe retrospectively identified adult CAG patients who underwent [¹⁸F]FET PET imaging (i) before diagnosis, (ii) at suspected relapse, or (iii) for response assessment at three institutions. Maximum and mean tumor-to-brain ratios (TBRmax, TBRmean) and metabolic tumor volumes were assessed according to the PET RANO 1.0 criteria. Diagnostic performance in differentiating treatment-related changes from tumor relapse was evaluated using ROC analysis and Fisher’s exact test.RESULTSWe evaluated 79 [¹⁸F]FET PET scans of 42 patients, including nine (21%) with actionable molecular targets. 65% of CAG WHO grade 1 and 100% of CAG WHO grades 2 or 3 had measurable [¹⁸F]FET uptake according to the PET RANO 1.0 criteria. In these patients, TBR values of CAG WHO grades 2 or 3 were significantly higher than in pilocytic astrocytomas (P<0.01). There was no significant difference in TBR between CAG with or without actionable targets (P>0.05). Following various treatments, response assessment according to the PET RANO 1.0 criteria differed from changes in MRI in 5 of 11 patients (45%). Treatment-related changes were confirmed neuropathologically or clinicoradiologically in 12 patients (43%). In CAG WHO grades 2 or 3, the accuracy of [¹⁸F]FET PET to identify treatment-related changes was 82% using single PET scans and 100% using serial PET imaging (P<0.05).CONCLUSION[¹⁸F]FET PET can add valuable information for the clinical management of patients with CAG.

Classification:

Contributing Institute(s):
  1. Physik der Medizinischen Bildgebung (INM-4)
Research Program(s):
  1. 5253 - Neuroimaging (POF4-525) (POF4-525)

Appears in the scientific report 2025
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Dokumenttypen > Präsentationen > Zusammenfassungen
Institutssammlungen > INM > INM-4
Workflowsammlungen > Öffentliche Einträge
Publikationsdatenbank

 Datensatz erzeugt am 2026-01-30, letzte Änderung am 2026-02-23


Externer link:
Volltext herunterladen
Volltext
Dieses Dokument bewerten:

Rate this document:
1
2
3
 
(Bisher nicht rezensiert)